These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects. Xu L; Zhang Y; Tian K; Chen X; Zhang R; Mu X; Wu Y; Wang D; Wang S; Liu F; Wang T; Zhang J; Liu S; Zhang Y; Tu C; Liu H J Exp Clin Cancer Res; 2018 Oct; 37(1):261. PubMed ID: 30373602 [TBL] [Abstract][Full Text] [Related]
6. Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma. Nedrow JR; Josefsson A; Park S; Ranka S; Roy S; Sgouros G J Nucl Med; 2017 Oct; 58(10):1560-1566. PubMed ID: 28522738 [TBL] [Abstract][Full Text] [Related]
7. Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy. Zhu B; Tang L; Chen S; Yin C; Peng S; Li X; Liu T; Liu W; Han C; Stawski L; Xu ZX; Zhou G; Chen X; Gao X; Goding CR; Xu N; Cui R; Cao P Oncogene; 2018 Sep; 37(36):4941-4954. PubMed ID: 29786078 [TBL] [Abstract][Full Text] [Related]
8. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Li T; Zhang C; Zhao G; Zhang X; Hao M; Hassan S; Zhang M; Zheng H; Yang D; Liu L; Mehraein-Ghomi F; Bai X; Chen K; Zhang W; Yang J Cancer Lett; 2020 May; 477():19-30. PubMed ID: 32120023 [TBL] [Abstract][Full Text] [Related]
9. PD-L1 positively regulates MET phosphorylation through inhibiting PTP1B. Lu S; Sun Z; Hu W; Yin S; Zhao C; Hu H Cancer Sci; 2021 May; 112(5):1878-1887. PubMed ID: 33583114 [TBL] [Abstract][Full Text] [Related]
13. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654 [TBL] [Abstract][Full Text] [Related]
14. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. Frydenlund N; Mahalingam M Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003 [TBL] [Abstract][Full Text] [Related]
15. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Blank C; Kuball J; Voelkl S; Wiendl H; Becker B; Walter B; Majdic O; Gajewski TF; Theobald M; Andreesen R; Mackensen A Int J Cancer; 2006 Jul; 119(2):317-27. PubMed ID: 16482562 [TBL] [Abstract][Full Text] [Related]
16. Modulation of T-cell activation by malignant melanoma initiating cells. Schatton T; Schütte U; Frank NY; Zhan Q; Hoerning A; Robles SC; Zhou J; Hodi FS; Spagnoli GC; Murphy GF; Frank MH Cancer Res; 2010 Jan; 70(2):697-708. PubMed ID: 20068175 [TBL] [Abstract][Full Text] [Related]
17. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. Jia L; Xi Q; Wang H; Zhang Z; Liu H; Cheng Y; Guo X; Zhang J; Zhang Q; Zhang L; Xue Z; Li Y; Da Y; Zhao P; Zhang R Biochem Biophys Res Commun; 2017 Jun; 488(2):425-431. PubMed ID: 28511795 [TBL] [Abstract][Full Text] [Related]
18. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575 [TBL] [Abstract][Full Text] [Related]
19. Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model. Contreras-Sandoval AM; Merino M; Vasquez M; Trocóniz IF; Berraondo P; Garrido MJ Oncotarget; 2016 Nov; 7(47):76891-76901. PubMed ID: 27764774 [TBL] [Abstract][Full Text] [Related]
20. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]